Wnt1 controls subchondral bone remodeling and osteoarthritis progression

Authors:
  • WXWeixin Xie
    Weixin Xie
  • ADAntonia Donat
    Antonia Donat
  • HPHaoyan Pan
    Haoyan Pan
  • RARuben Augustin
    Ruben Augustin
  • TSTill Schoberwalter
    Till Schoberwalter
  • CGChiara Gerriets
    Chiara Gerriets
  • JSJan Sevecke
    Jan Sevecke
  • CECordula Erdmann
    Cordula Erdmann
  • SSSaskia Schröder
    Saskia Schröder
  • IBIsabell Behrens
    Isabell Behrens

Abstract
Despite mounting evidence emphasizing the role of abnormal subchondral bone remodeling in the progression of osteoarthritis (OA), clinical translation has produced disappointing results. Here, we demonstrate an increased expression of Wnt1, a key Wnt ligand with potent osteoanabolic effects, during OA progression in human and murine subchondral bone. Temporarily overexpressing Wnt1 in osteoblasts in the early phase after anterior cruciate ligament transection (ACLT)-induced OA has no effect on cartilage degeneration; however, it contributes to increased subchondral bone mass and alleviates subchondral bone loss. In contrast, late-phase induction of Wnt1 in osteoblasts exacerbates OA severity by inducing aberrant subchondral bone sclerosis, where inflammation-induced secreted frizzled-related protein 2 (Sfrp2) in the subchondral bone potentiates the harmful effects of Wnt1. Moreover, mice with a global inactivating Wnt1 G177C mutation, which clinically causes osteogenesis imperfecta type XV, display low subchondral bone mass, are resistant to ACLT-induced subchondral bone loss and exhibit attenuated OA progression. Taken together, these findings identify a pathophysiological role for Wnt1 in subchondral bone remodeling and OA progression that could represent a promising therapeutic target.
Funding Information
  • Deutsche Forschungsgemeinschaft (KE 2179/11-1)
  • Deutsche Forschungsgemeinschaft (RO 5925/5-1)
  • Deutsche Forschungsgemeinschaft (BA 7863/1-1)

This publication has 106 references indexed in Scilit: